{"protocolSection": {"identificationModule": {"nctId": "NCT01123980", "orgStudyIdInfo": {"id": "BIASP-3756"}, "secondaryIdInfos": [{"id": "U1111-1114-4112", "type": "OTHER", "domain": "WHO"}, {"id": "JapicCTI-101139", "type": "OTHER", "domain": "JAPIC"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment", "officialTitle": "An Open-labelled, Randomised, Parallel Group, 3 Week run-in and 24 Week Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Chinese and Japanese Insulin Naive Subjects With Type 2 Diabetes", "acronym": "EasyMix"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05"}, "primaryCompletionDateStruct": {"date": "2011-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-13", "studyFirstSubmitQcDate": "2010-05-13", "studyFirstPostDateStruct": {"date": "2010-05-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-01", "resultsFirstSubmitQcDate": "2012-06-01", "resultsFirstPostDateStruct": {"date": "2012-07-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-10", "lastUpdatePostDateStruct": {"date": "2017-02-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin and glimepiride in Chinese and Japanese subjects with type 2 diabetes who have never received insulin before.\n\nThe trial is conducted as a phase 4 trial in China and phase 3 in Japan."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 521, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BIAsp 30", "type": "EXPERIMENTAL", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride", "interventionNames": ["Drug: biphasic insulin aspart 30", "Drug: metformin", "Drug: glimepiride"]}, {"label": "Insulin glargine", "type": "ACTIVE_COMPARATOR", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride", "interventionNames": ["Drug: metformin", "Drug: glimepiride", "Drug: insulin glargine"]}], "interventions": [{"type": "DRUG", "name": "biphasic insulin aspart 30", "description": "Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.", "armGroupLabels": ["BIAsp 30"]}, {"type": "DRUG", "name": "metformin", "description": "China: Tablets, 500 mg. Min. 1500 mg/day.\n\nJapan: Tablets, 250 mg. Min 500 mg/day.", "armGroupLabels": ["BIAsp 30", "Insulin glargine"]}, {"type": "DRUG", "name": "glimepiride", "description": "China: Tablets, 2 mg. Min. 4 mg/day.\n\nJapan: Tablets, 1 mg. Min. 4 mg/day.", "armGroupLabels": ["BIAsp 30", "Insulin glargine"]}, {"type": "DRUG", "name": "insulin glargine", "description": "Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.", "armGroupLabels": ["Insulin glargine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c)", "timeFrame": "Week 0, week 24"}], "secondaryOutcomes": [{"measure": "9-point Plasma Glucose Profiles", "description": "Glycaemic control measured by 9-point plasma glucose (SPMG) profiles. The 9 timepoints for self-measurement during the day were: before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, before bedtime, at 2-4 a.m. and before breakfast the following day.", "timeFrame": "Week 24"}, {"measure": "Percentage of Subjects Achieving HbA1c Below 7.0%", "description": "The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment", "timeFrame": "Week 24"}, {"measure": "Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%", "description": "The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment", "timeFrame": "Week 24"}, {"measure": "Number of Hypoglycaemic Episodes - All", "timeFrame": "Weeks 0-24"}, {"measure": "Number of Hypoglycaemic Episodes - Severe and Minor", "description": "Hypoglycaemic episodes (hypos) summarised based on American Diabetes Association classification (severe, documented symptomatic, asymptomatic, probable symptomatic, and relative hypoglycaemia) and according to additional definition (minor hypoglycaemia). Severe hypos: requiring another person to actively administer resuscitative actions. Minor hypos: symptoms with plasma glucose below 3.1 mmol/L (56 mg/dl), or any asympomatic plasma glucose below 3.1 mmol/L.", "timeFrame": "Weeks 0-24"}, {"measure": "Number of Hypoglycaemic Episodes", "description": "All episodes classified into nocturnal (time of onset between 00:00 (included) and 05:59 (included)).", "timeFrame": "Weeks 0-24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes treated with a maximum of three different types of oral anti-diabetic drugs (OADs) (including traditional Chinese medicine which contains active ingredients of known OADs) for more than 6 months\n* Unchanged total daily dose of at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) metformin for the last two months\n* Unchanged total daily dose of at least half maximum recommended total daily dose of any insulin secretagogue for the last two months\n* Insulin naive\n* HbA1c between 7.0% and 10.0%\n* FPG (fasting plasma glucose) equal to or above 6.1 mmol/L (110mg/dL)\n* Body Mass Index (BMI) below 40.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Treatment with any thiazolidinedione (TZD) and GLP-1 (glucagon like peptide-1) receptor antagonists during the last 3 months before Visit 1 in this trial\n* Any disease or condition which the Investigator feels would interfere with the trial\n* Any contraindication to metformin or glimepiride (according to local labelling)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing", "zip": "100029", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing", "zip": "100101", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing", "zip": "100191", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing", "zip": "100700", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beijing", "state": "Beijing", "zip": "100853", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chongqing", "state": "Chongqing", "zip": "400010", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fuzhou", "state": "Fujian", "zip": "350025", "country": "China", "geoPoint": {"lat": 26.06139, "lon": 119.30611}}, {"facility": "Novo Nordisk Investigational Site", "city": "Harbin", "state": "Heilongjiang", "zip": "150001", "country": "China", "geoPoint": {"lat": 45.75, "lon": 126.65}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zhengzhou", "state": "Henan", "zip": "450052", "country": "China", "geoPoint": {"lat": 34.75778, "lon": 113.64861}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210012", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210029", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wuxi", "state": "Jiangsu", "zip": "214023", "country": "China", "geoPoint": {"lat": 31.56887, "lon": 120.28857}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanchang", "state": "Jiangxi", "zip": "330006", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dalian", "state": "Liaoning", "zip": "116011", "country": "China", "geoPoint": {"lat": 38.91222, "lon": 121.60222}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shenyang", "state": "Liaoning", "zip": "110004", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shenyang", "state": "Liaoning", "zip": "110021", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novo Nordisk Investigational Site", "city": "Xi'an", "state": "Shaanxi", "zip": "710061", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tianjin", "state": "Tianjin", "zip": "300052", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tianjin", "state": "Tianjin", "zip": "300070", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shenyang", "zip": "110001", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tianjin", "zip": "300211", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Asahikawa-shi, Hokkaido", "zip": "078 8510", "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Chuo-ku, Tokyo", "zip": "103 0002", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Novo Nordisk Investigational Site", "city": "Gifu city, Gifu", "zip": "5008717", "country": "Japan", "geoPoint": {"lat": 35.42291, "lon": 136.76039}}, {"facility": "Novo Nordisk Investigational Site", "city": "Higashi-ku", "zip": "812 8582", "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Kumamoto-shi,Kumamoto", "zip": "862 0976", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "Novo Nordisk Investigational Site", "city": "Minato-ku", "zip": "108 0073", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Novo Nordisk Investigational Site", "city": "Osaka-shi, Osaka", "zip": "545 8586", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Novo Nordisk Investigational Site", "city": "Osaka-shi", "zip": "5300025", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Novo Nordisk Investigational Site", "city": "Shimotsuka-gun", "zip": "321 0293", "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Shimotsuke-shi, Tochigi", "zip": "329 0433", "country": "Japan"}, {"facility": "Novo Nordisk Investigational Site", "city": "Shizuoka-shi", "zip": "424 0853", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tagajo-shi", "zip": "985 0852", "country": "Japan", "geoPoint": {"lat": 38.3, "lon": 141.0}}, {"facility": "Novo Nordisk Investigational Site", "city": "Yokohama-shi", "zip": "235 0045", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}]}, "referencesModule": {"references": [{"pmid": "23998560", "type": "RESULT", "citation": "Yang W, Xu X, Liu X, Yang G, Seino Y, Andersen H, Jinnouchi H. Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes. Curr Med Res Opin. 2013 Dec;29(12):1599-608. doi: 10.1185/03007995.2013.838155. Epub 2013 Sep 23."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "At the screening, eligible subjects entered the run-in period before being randomised. During the 3 week run-in period, subjects switched from insulin secretagogue to glimepiride. During the last 2 weeks, the total dose of glimepiride was kept at 4mg/day. Subjects continued their pre-trial metformin dose.", "recruitmentDetails": "The trial was conducted at 35 sites in two countries: China (21 sites) and Japan (14 sites).", "groups": [{"id": "FG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "FG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "261"}, {"groupId": "FG001", "numSubjects": "260"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "242"}, {"groupId": "FG001", "numSubjects": "236"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "24"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "BG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "261"}, {"groupId": "BG001", "value": "260"}, {"groupId": "BG002", "value": "521"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.6", "spread": "9.4"}, {"groupId": "BG001", "value": "56.1", "spread": "9.9"}, {"groupId": "BG002", "value": "56.3", "spread": "9.6"}]}]}]}, {"title": "Gender", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "119"}, {"groupId": "BG002", "value": "233"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "147"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "288"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "261"}, {"groupId": "BG001", "value": "260"}, {"groupId": "BG002", "value": "521"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "China", "categories": [{"measurements": [{"groupId": "BG000", "value": "210"}, {"groupId": "BG001", "value": "212"}, {"groupId": "BG002", "value": "422"}]}]}, {"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "99"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "165.3", "spread": "8.6"}, {"groupId": "BG001", "value": "165.2", "spread": "8.2"}, {"groupId": "BG002", "value": "165.3", "spread": "8.4"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.0", "spread": "11.6"}, {"groupId": "BG001", "value": "70.6", "spread": "12.5"}, {"groupId": "BG002", "value": "70.3", "spread": "12.1"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25.53", "spread": "3.39"}, {"groupId": "BG001", "value": "25.76", "spread": "3.44"}, {"groupId": "BG002", "value": "25.65", "spread": "3.41"}]}]}]}, {"title": "HbA1c (glycosylated haemoglobin) at randomisation", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.7", "spread": "0.88"}, {"groupId": "BG001", "value": "8.14", "spread": "0.86"}, {"groupId": "BG002", "value": "8.15", "spread": "0.87"}]}]}]}, {"title": "Duration of diabetes", "description": "Number of years since diagnosis", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.23", "spread": "7.15"}, {"groupId": "BG001", "value": "9.47", "spread": "6.61"}, {"groupId": "BG002", "value": "9.35", "spread": "6.88"}]}]}]}, {"title": "Diabetic complications at baseline", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "147"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "189"}, {"groupId": "BG001", "value": "185"}, {"groupId": "BG002", "value": "374"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin (HbA1c)", "populationDescription": "Full analysis set using LOCF (last observation carried forward) consists of all randomised subjects who were exposed to at least one dose of trial product(s)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, week 24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.56", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: The mean treatment difference (BIAsp 30 minus insulin glargine) \\> 0.4%. HA: The mean treatment difference (BIAsp 30 minus insulin glargine) =\\< 0.4%. Sample size was calculated to achieve a power of at least 90%, assuming an equal change in HbA1c and a common standard deviation of 1.25%", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority was considered to be confirmed if the upper bound of the two-sided 95% confidence interval (CI) was below or equal to 0.4% or equivalent if the p-value for the one-sided test of H0: D \\> 0.4% against HA: D =\\< 0.4%, was less than or equal to 2.5%, where D is the mean treatment difference (investigational product minus comparator). Furthermore, superiority of BIAsp 30 OD over insulin glargine OD was shown if the upper limit of the 95% CI for the difference is lower than 0%", "pValue": "< 0.001", "pValueComment": "The p-values correspond to one-sided hypotheses of either non-inferiority or superiority, statistical significance level is 2.5%.", "statisticalMethod": "ANCOVA", "statisticalComment": "The estimates are from a normal linear regression model with treatment, country and previous OADs as factors and baseline HbA1c as a covariate", "paramType": "Mean Difference (Net)", "paramValue": "-0.12", "ciPctValue": "95", "ciLowerLimit": "-0.25", "ciUpperLimit": "0.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.07"}]}, {"type": "SECONDARY", "title": "9-point Plasma Glucose Profiles", "description": "Glycaemic control measured by 9-point plasma glucose (SPMG) profiles. The 9 timepoints for self-measurement during the day were: before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, before bedtime, at 2-4 a.m. and before breakfast the following day.", "populationDescription": "Full analysis set using LOCF (last observation carried forward) consists of all randomised subjects who were exposed to at least one dose of the trial product(s).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"title": "Before breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.46", "spread": "0.09"}, {"groupId": "OG001", "value": "6.49", "spread": "0.09"}]}]}, {"title": "2 hours after breakfast", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.18", "spread": "0.19"}, {"groupId": "OG001", "value": "10.11", "spread": "0.19"}]}]}, {"title": "Before lunch", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.35", "spread": "0.17"}, {"groupId": "OG001", "value": "7.22", "spread": "0.17"}]}]}, {"title": "2 hours after lunch", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.50", "spread": "0.20"}, {"groupId": "OG001", "value": "10.22", "spread": "0.20"}]}]}, {"title": "Before dinner", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.67", "spread": "0.16"}, {"groupId": "OG001", "value": "7.03", "spread": "0.16"}]}]}, {"title": "2 hours after dinner", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.36", "spread": "0.19"}, {"groupId": "OG001", "value": "10.88", "spread": "0.19"}]}]}, {"title": "Before bedtime", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.14", "spread": "0.18"}, {"groupId": "OG001", "value": "9.39", "spread": "0.18"}]}]}, {"title": "At 2-4 a.m.", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.58", "spread": "0.13"}, {"groupId": "OG001", "value": "7.06", "spread": "0.13"}]}]}, {"title": "Before breakfast the following day", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.51", "spread": "0.10"}, {"groupId": "OG001", "value": "6.35", "spread": "0.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.03", "ciPctValue": "95", "ciLowerLimit": "-0.24", "ciUpperLimit": "0.19", "estimateComment": "Before breakfast"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.07", "ciPctValue": "95", "ciLowerLimit": "-0.45", "ciUpperLimit": "0.58", "estimateComment": "Two hours after breakfast"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.14", "ciPctValue": "95", "ciLowerLimit": "-0.31", "ciUpperLimit": "0.58", "estimateComment": "Before lunch"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.28", "ciPctValue": "95", "ciLowerLimit": "-0.26", "ciUpperLimit": "0.82", "estimateComment": "Two hours after lunch"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.64", "ciPctValue": "95", "ciLowerLimit": "0.22", "ciUpperLimit": "1.06", "estimateComment": "Before dinner"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.51", "ciPctValue": "95", "ciLowerLimit": "-2.03", "ciUpperLimit": "-1.00", "estimateComment": "Two hours after dinner"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.25", "ciPctValue": "95", "ciLowerLimit": "-1.73", "ciUpperLimit": "-0.78", "estimateComment": "Bedtime"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.47", "ciPctValue": "95", "ciLowerLimit": "-0.81", "ciUpperLimit": "-0.13", "estimateComment": "02 - 04 a.m."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Repeated measures mixed model with an unstructured residual covarience matrix, including treatment, time, the treatment-by-time interaction, country and previous OADs as factors.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "P-value for parallelism is overall test for parallel time profiles between treatment groups.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.17", "ciPctValue": "95", "ciLowerLimit": "-0.06", "ciUpperLimit": "0.40", "estimateComment": "Before breakfast the following day"}]}, {"type": "SECONDARY", "title": "Percentage of Subjects Achieving HbA1c Below 7.0%", "description": "The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment", "populationDescription": "Full analysis set using LOCF (last observation carried forward) consists of all randomised subjects who were exposed to at least one dose of the trial product(s).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage (%) of subjects", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.1"}, {"groupId": "OG001", "value": "30.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The responder analysis was based on logistic regression model using treatment, country and previous OAD therapy (with or without a third OAD) as factors and baseline HbA1c as covariate.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8583", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.96", "ciPctValue": "95", "ciLowerLimit": "0.64", "ciUpperLimit": "1.46", "estimateComment": "The odds ratio and 95% confidence interval is for the HbA1c less than 7% treatment target were included."}]}, {"type": "SECONDARY", "title": "Percentage of Subjects Achieving HbA1c Below or Equal to 6.5%", "description": "The percentage of subjects achieving the treatment target for glycosylated haemoglobin A1c after 24 weeks of treatment", "populationDescription": "Full analysis set using LOCF (last observation carried forward) consists of all randomised subjects who were exposed to at least one dose of the trial product(s).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage (%) of subjects", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.9"}, {"groupId": "OG001", "value": "14.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The responder analysis was based on logistic regression model using treatment, country and previous OAD therapy (with or without a third OAD) as factors and baseline HbA1c as covariate.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8013", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "1.07", "ciPctValue": "95", "ciLowerLimit": "0.64", "ciUpperLimit": "1.79", "estimateComment": "The odds ratio and 95% confidence interval is for the HbA1c below or equal to 6.5% treatment target were included."}]}, {"type": "SECONDARY", "title": "Number of Hypoglycaemic Episodes - All", "populationDescription": "The safety analysis set contains all subjects exposed to at least one dose of investigational product(s).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "745"}, {"groupId": "OG001", "value": "605"}]}]}]}, {"type": "SECONDARY", "title": "Number of Hypoglycaemic Episodes - Severe and Minor", "description": "Hypoglycaemic episodes (hypos) summarised based on American Diabetes Association classification (severe, documented symptomatic, asymptomatic, probable symptomatic, and relative hypoglycaemia) and according to additional definition (minor hypoglycaemia). Severe hypos: requiring another person to actively administer resuscitative actions. Minor hypos: symptoms with plasma glucose below 3.1 mmol/L (56 mg/dl), or any asympomatic plasma glucose below 3.1 mmol/L.", "populationDescription": "The safety analysis set contains all subjects exposed to at least one dose of investigational product(s).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"title": "Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "125"}]}]}]}, {"type": "SECONDARY", "title": "Number of Hypoglycaemic Episodes", "description": "All episodes classified into nocturnal (time of onset between 00:00 (included) and 05:59 (included)).", "populationDescription": "The safety analysis set contains all subjects exposed to at least one dose of investigational product(s).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Weeks 0-24", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}, {"id": "OG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "261"}, {"groupId": "OG001", "value": "260"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "63"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a timespan of 24 weeks.", "description": "The safety analysis set contains all subjects exposed to at least one dose of investigational products.", "eventGroups": [{"id": "EG000", "title": "BIAsp 30", "description": "0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride", "seriousNumAffected": 2, "seriousNumAtRisk": 261, "otherNumAffected": 26, "otherNumAtRisk": 261}, {"id": "EG001", "title": "Insulin Glargine", "description": "0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride", "seriousNumAffected": 5, "seriousNumAtRisk": 260, "otherNumAffected": 28, "otherNumAtRisk": 260}], "seriousEvents": [{"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 260}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 260}]}, {"term": "Adrenal adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 260}]}, {"term": "Multiple myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 260}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 260}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 260}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 13.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 31, "numAffected": 26, "numAtRisk": 261}, {"groupId": "EG001", "numEvents": 37, "numAffected": 28, "numAtRisk": 260}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk reserves the right not to release data until specified milestones. This includes the right not to release interim results from clinical trials. At the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000061265", "term": "Biphasic Insulins"}, {"id": "C000557564", "term": "Insulin aspart, insulin aspart protamine drug combination 30:70"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M29799", "name": "Biphasic Insulins", "asFound": "Institutional", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M14342", "name": "Protamines", "relevance": "LOW"}, {"id": "M350709", "name": "Insulin aspart, insulin aspart protamine drug combination 30:70", "asFound": "One side", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}